DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Filanesib is an investigational drug.
There have been 4 clinical trials for Filanesib. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and [disabled in preview]. The leading clinical trial sponsors are Array BioPharma, PETHEMA Foundation, and Celgene Corporation.
There are fifteen US patents protecting this investigational drug and one hundred and thirteen international patents.
Recent Clinical Trials for Filanesib
|Pembrolizumab (MK-3475) in MM Patients With Residual Disease||Adknoma Health Research||Phase 2|
|Pembrolizumab (MK-3475) in MM Patients With Residual Disease||Merck Sharp & Dohme Corp.||Phase 2|
|Pembrolizumab (MK-3475) in MM Patients With Residual Disease||PETHEMA Foundation||Phase 2|
Top disease conditions for Filanesib
Top clinical trial sponsors for Filanesib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Filanesib||Start Trial||Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)||BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)||Start Trial|
|Filanesib||Start Trial||Formylated N-heterocyclic derivatives as FGFR4 inhibitors||NOVARTIS AG (Basel, CH)||Start Trial|
|Filanesib||Start Trial||Chemical entities that kill senescent cells for use in treating age-related disease||UNITY BIOTECHNOLOGY, INC. (San Francisco, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|